Quick Search 
Drugs of the Future
Register or sign in

Drugs Fut 2007, 32(3): 209
ISSN 0377-8282
e-ISSN 2013-0368
Copyright 2007 Clarivate
CCC: 0377-8282
DOI: 10.1358/dof.2007.032.03.1083308
Viera, M.H., Perez, O.A., Berman, B.
The chemically modified tetracycline (CMT) incyclinide (COL-3, CMT-3) has been extensively studied as a potential new therapeutic agent for allergic conditions, inflammatory (i.e., arthritis, acute respiratory distress syndrome [ARDS], septic shock syndrome, acne and rosacea), neoplastic (i.e., Kaposi's sarcoma, colon carcinoma, melanoma, prostate cancer) and infectious (fungal) diseases. The most prominent characteristic of CMTs is their lack of antibacterial properties, accompanied by retention, or even enhancement, of metalloproteinase (MMP) inhibition. Studies have demonstrated that incyclinide is a modulator of MMP-2, MMP-9 and serine proteases, as well as cytokines and interleukins that are crucial in the development of inflammation, angiogenesis and tumorigenesis. Furthermore, toxicology studies have demonstrated that incyclinide is relatively safe.

Full Text: HTMLPDF 

© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences